Forge Nano Holdings, Inc.
NANODrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
Get an email about NANO's next catalysts
Track Forge Nano Holdings (NANO) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
1 upcoming, 0 past
FBX-101 Phase 2 Est. Readout (REKLAIM)
Estimated primary completion for FBX-101 trial (NCT05739643) in Krabbe Disease. Topline data typically follows completion by weeks to months.
Source| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
FBX-101 | Phase 2 | Krabbe Disease | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Forge Nano Holdings, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Forge Nano Holdings, Inc.'s (NANO) pipeline across Phase 2. Its lead program is FBX-101 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Forge Nano Holdings, Inc.'s next FDA catalyst?→
Forge Nano Holdings, Inc.'s (NANO) next tracked catalyst is a Phase 2 readout expected November 15, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track NANO biotech catalysts?→
Add NANO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Forge Nano Holdings, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.